|
Patients achieving a EULAR good response (CRP criteria)
|
98/259 (37.8%)
|
165/415 (39.8%)
|
83/157 (52.9%)
|
|
Patients achieving ACR20 response
|
179/261 (68.6%)
|
318/418 (76.1%)
|
142/161 (88.2%)
|
|
Patients achieving ACR50 response
|
103/261 (39.5%)
|
195/418 (46.7%)
|
106/161 (65.8%)
|
|
Patients achieving ACR70 response
|
47/261 (18.0%)
|
97/418 (23.2%)
|
68/161 (42.2%)
|
|
DAS28-CRP
|
|
Patients achieving low disease activity: DAS28-CRP ≤ 3.2
|
101/259 (39.0%)
|
166/415 (40.0%)
|
84/157 (53.5%)
|
|
Patients achieving remission: DAS28-CRP < 2.6
|
60/259 (23.2%)
|
101/415 (24.3%)
|
59/157 (37.6%)
|
|
CDAI
|
|
Patients achieving low disease activity: CDAI ≤ 10.0
|
93/259 (35.9%)
|
172/416 (41.3%)
|
92/161 (57.1%)
|
|
Patients achieving remission: CDAI ≤ 2.8
|
22/259 (8.5%)
|
50/416 (12.0%)
|
27/161 (16.8%)
|
|
SDAI
|
|
Patients achieving low disease activity: SDAI ≤ 11.0
|
96/259 (37.1%)
|
172/415 (41.4%)
|
89/157 (56.7%)
|
|
Patients achieving remission: SDAI ≤ 3.3
|
22/259 (8.5%)
|
53/415 (12.8%)
|
29/157 (18.5%)
|
|
Patients achieving Boolean remission
|
6/260 (2.3%)
|
12/416 (2.9%)
|
12/161 (7.5%)
|
|
Patients achieving HAQ-DI MCID (≥ 0.22)
|
15/261 (5.7%)
|
36/418 (8.6%)
|
30/161 (18.6%)
|
